Samsung Bioepis Begins Direct Sales of Two Bone Disorder Treatments in Europe

10 Products Commercialized in Europe in 10 Years

Samsung Bioepis announced on December 2 that it will begin direct sales of two bone disorder treatments, Obodens and Xbrick, in Europe in December and January of next year, respectively.

Photo of Obodens-Xbrick product. Samsung Bioepis

Obodens and Xbrick are biosimilars of Prolia and Xgeva, which were developed by the global pharmaceutical company Amgen. Depending on the dosage and administration schedule of the denosumab ingredient, they are classified as an osteoporosis treatment (Obodens) and a treatment for giant cell tumors of bone and other conditions (Xbrick).

Since launching the autoimmune disease treatment Benepali (ingredient: etanercept) in Europe in 2016, Samsung Bioepis has now commercialized a total of 10 products in the European market over the past 10 years, expanding its portfolio across a wide range of disease areas in immunology, oncology, ophthalmology, and hematology with the addition of these two new products.

In addition, Samsung Bioepis plans to directly sell Obodens and Xbrick through a tailored strategy centered on its European subsidiary, leveraging the commercial capabilities and expertise it has built up in the European market.

Linda Choi, Executive Vice President and Head of Commercial at Samsung Bioepis, stated, "We are launching Obodens and Xbrick based on our experience in developing and marketing biosimilars across various therapeutic areas in the global market. We will continue our efforts to provide patients with more treatment opportunities through biosimilars and to enhance social value by reducing healthcare costs."

This content was produced with the assistance of AI translation services.